News >

Navigating Triplet Therapies in Relapsed/Refractory Multiple Myeloma

Caroline Seymour
Published: Thursday, Feb 13, 2020

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorders and director of Clinical Research in Hematologic Malignancies at Levine Cancer Institute, Atrium Health

Saad Z. Usmani, MD

To determine the best way to navigate treatment decisions for patients with relapsed/refractory multiple myeloma, especially with regard to triplet regimens, several factors must be considered, according to Saad Z. Usmani, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication